Clinical Trials
46 trialsNCT01676818 2025-11-06
Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer
University of Southern California
Phase 2 Completed
NCT03899805 2025-08-28
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Phase 2 Completed
NCT06533722 2025-06-10
Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Completed
NCT02061085 2025-06-08
MERIBEL
MedSIR
Phase 2 Completed
NCT03222856 2025-06-05
KELLY
MedSIR
Phase 2 Completed
NCT01827787 2024-11-06
Eribulin in HER2 Negative Metastatic BrCa
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03840772 2024-09-20
ERASING
Italian Sarcoma Group
Phase 2 Completed
NCT04464174 2024-07-26
PATHFINDER
MedSIR
Phase 2 Completed
NCT02035813 2024-06-04
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
University of Ulm
Phase 2 Completed
NCT02640508 2024-05-09
Eribulin and Lenvatinib in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT03051659 2024-03-06
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00879086 2023-06-22
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT01104155 2023-06-22
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
Eisai Inc.
Phase 2 Completed
NCT01268150 2023-06-22
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT01269346 2023-06-22
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT01439282 2023-06-22
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT05206656 2022-11-23
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
Hunan Cancer Hospital
Phase 2 Completed
NCT03441360 2022-10-05
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Eisai Inc.
Phase 2 Completed
NCT03810976 2022-06-16
A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma
Yonsei University
Phase 2 Completed
NCT01705691 2021-10-06
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
NSABP Foundation Inc
Phase 2 Completed
NCT01593020 2021-09-22
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02581839 2020-07-30
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01908101 2020-07-23
Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
University of Washington
Phase 2 Completed
NCT02263495 2020-07-14
EG_PG
Asan Medical Center
Phase 2 Completed
NCT02097238 2020-05-19
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02178241 2019-12-16
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01328249 2019-08-20
Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT02481050 2018-11-15
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT01613768 2018-09-28
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
University of Washington
Phase 2 Completed
NCT01401959 2018-06-15
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00334893 2017-11-29
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01669252 2017-11-06
NeoEribulin
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT00383760 2017-10-20
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
National Cancer Institute (NCI)
Phase 2 Completed
NCT00413192 2017-04-26
E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma
Eisai Inc.
Phase 2 Completed
NCT01427933 2017-02-06
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01527487 2016-11-04
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01458249 2016-03-28
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)
Eisai Inc.
Phase 2 Completed
NCT01941407 2016-03-17
ESMERALDA
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT00337129 2015-08-25
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00400829 2015-01-07
E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00246090 2014-07-14
A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
Eisai Inc.
Phase 2 Completed
NCT00278993 2014-07-14
Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
Eisai Inc.
Phase 2 Completed
NCT00337077 2014-06-23
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00965523 2013-08-15
Study of E7389 for Advanced or Metastatic Breast Cancer
Eisai Inc.
Phase 2 Completed
NCT00097721 2013-04-22
A Study of E7389 in Advanced/Metastatic Breast Cancer Patients
Eisai Inc.
Phase 2 Completed
NCT00100932 2012-03-27
Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy
Eisai Inc.
Phase 2 Completed